ニソルジピン
2,6-ジメチル-4-(2-ニトロフェニル)-1,4-ジヒドロピリジン-3,5-ジカルボン酸3-イソブチル5-メチル · ニソルジピン · 1,4-ジヒドロ-2,6-ジメチル-4-(2-ニトロフェニル)-3,5-ピリジンジカルボン酸3-メチル5-イソブチル · リオハード · ニノバルシン · ニソミナード · ニカミール · バイミカード
識別子と物理属性
| CAS No. | 63675-72-9 |
|---|---|
| 分子式 | C20H24N2O6 |
| 平均分子量 | 388.4 g/mol |
| 単同位体質量 | 388.16343649 g/mol |
| SMILES | COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-] |
| InChIKey | VKQFCGNPDRICFG-UHFFFAOYSA-N |
| PubChem CID | 4499 |
| ChEMBL | CHEMBL1726 |
| ChEBI | CHEBI:76917 |
| EC No. | 264-407-7 |
| DTXSID | DTXSID0023371 |
| 現地名 | ニソルジピン |
化学・物理的性質
| XLogP | 3.3 |
|---|---|
| 極性表面積 | 110 |
| 水素結合供与体数 | 1 |
| 水素結合受容体数 | 7 |
| 回転可能結合数 | 7 |
| 重原子数 | 28 |
| 形式電荷 | 0 |
| 複雑度 | 704 |
| LogP（分配係数） | 3.263.1 |
| 溶解度 | 5.77e-03 g/LDMSO：>10mg/mL |
| Physical Description | Solid |
| Kovats Retention Index | 2679 |
| Collision Cross Section | 195.5 Ų [M+Na]+ [CCS Type: DTBuffer gas: N2Ionization: ESI+Dataset: TOXCASTSource Identifier: DTXSID0023371]190.3 Ų [M+Na]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]184.16 Ų [M+H]+ [CCS Type: TW193.15 Ų [M+K]+ [CCS Type: TW187.2 Ų [M+H]+ [CCS Type: TW |
| 融点 | 147-148°C |
| 沸点 | 503.3±50.0 °C(Predicted) |
| 密度 | 1.205±0.06 g/cm3(Predicted) |
| 貯蔵条件 | room temp |
| 外観・状態 | 粉 |
| pKa（酸解離定数） | 2.67±0.70(Predicted) |
| 色 | 黄色 |
| Merck | 14,6565 |
| InChI | 1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3 |
| InChIKey | VKQFCGNPDRICFG-UHFFFAOYSA-N |
| SMILES | COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OCC(C)C |
| CAS データベース | 63675-72-9(CAS DataBase Reference) |
| NISTの化学物質情報 | Nisoldipine(63675-72-9) |
化学的特性
Nisoldipine D4 is Light Tan Crystals
安全性と法規制
| GHS 分類 | WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]H312 (60.9%): Harmful in contact with skin [Warning Acute toxicity, dermal]H361 (36.2%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]H411 (34.8%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]P203, P264, P270, P273, P280, P301+P317, P302+P352, P317, P318, P321, P330, P362+P364, P391, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 69 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (100%)Acute Tox. 4 (60.9%)Repr. 2 (36.2%)Aquatic Chronic 2 (34.8%) |
| 有害作用 | Though nisoldipine is well-tolerated among patients, the drug does have some side effects mainly associated with its vasodilating property. Common adverse effects associated with nisoldipine include flushing, vasodilation (4%), hypotension, syncope, peripheral edema (7% to 29%,dose-related), headache (22%), dizziness (3% to 10%), and nausea (2%).Additionally, adverse reactions such as chest pain (2%), palpitations (3%), dermatitis (2%), pharyngitis (5%), and sinusitis (3%) are reported in patients taking nisoldipine. Occasional adverse effects (less than 1% of the population) include anemia, anxiety, alopecia, dysphagia, and gingival hyperplasia.In less than 1% of the population taking nisoldipine, the following adverse reactions are reported in postmarketing surveillance.Increased blood urea nitrogen, increased creatine phosphokinase, abnormal hepatic function, increased serum creatinine, anorexia, hepatomegaly, abnormal dreams, amnesia, ataxia, cerebral ischemia, cerebrovascular accident, depression, drowsiness, insomnia, abnormal T waves on ECG, ejection murmur (systolic), first-degree atrioventricular block, atrial fibrillation, supraventricular tachycardia, amblyopia, blepharitis, diaphoresis, glaucoma, keratoconjunctivitis, exfoliative dermatitis, facial edema, dermal ulcer, hypersensitivity reaction, maculopapular rash, increased appetite, oral mucosa ulcer, hematuria, colitis, diarrhea, dysgeusia, dyspepsia, dysuria, epistaxis, gastritis, gastrointestinal bleeding, glossitis, leukopenia, malaise, melena, fever, flu-like symptoms, arthralgia, arthritis, gout, bruise, herpes simplex infection, herpes zoster, cellulitis, dyspnea, decreased libido, and gynecomastia is reported by manufacturer's product label. |
用途
用途
薬理・生理作用研究用。
用途
カルシウム拮抗剤です。L 型 電位依存性カルシウムチャネルのN 部位に結 合し、細胞内へのカルシウムイオン流入を抑 制する作用を示します。
用途
ニソルジピン（国際一般名、英: Nisoldipine）は、ジヒドロピリジン系カルシウムチャネル拮抗薬の一つ。 血管平滑筋細胞のカルシウムチャネルに作用し、細胞内へのカルシウムの流入を阻害する。高血圧症、狭心症に対し有効である。
説明
Nisoldipine D4 is another long-acting dihydropyridine calcium channel blocker effective in the treatment of hypertension and angina pectoris. It is reported to have little or no cardiodepressive activity and to be more effective than nifedipine in reducing blood pressure in hypertensives. Nisoldipine has also been shown to be effective in the management of congestive heart failure. Reduction in dosage is necessary in patients with hepatic, but not renal impairment.
使用
Labeled Nisoldipine, intended for use as an internal standard for the quantification of Nisoldipine by GC- or LC-mass spectrometry.
一般的な説明
In vitro studies show that the effects ofnisoldipine, 1,4-dihydro-2, 6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinecarboxylic acid methyl 2-methylpropyl ester(Sular), on contractile processes are selective, with greaterpotency on vascular smooth muscle than on cardiac muscle.Nisoldipine is highly metabolized, with five majormetabolites identified. As with most of the dihydropyridines,the cytochrome P450 (CYP) 3A4 isozyme is mainlyresponsible for the metabolism of nisoldipine. The majorbiotransformation pathway appears to involve the hydroxylationof the isobutyl ester side chain. This particular metabolitehas approximately 10% of the activity of the parentcompound.